EnsoData has acquired sleep diagnostic technology from Resonea that will add acoustic flow and microphone channels to its platform.
The two channels will be integrated into a mobile app that uses no proprietary medical hardware to prescreen for sleep apnea.
The U.S. Food and Drug Administration (FDA)-cleared app, which is installed on a patient's smartphone, records auditory data through the microphone and acoustic flow channels while the patient sleeps, securely transferring data to the cloud and enabling an acoustic analysis to identify events suggestive of sleep apnea or other disorders, EnsoData said in a statement.
Moreover, the firm added, by pairing an FDA-cleared pulse oximeter with the app, clinicians can add more clinical data to the analysis and reporting available in the artificial intelligence-driven EnsoSleep PPG diagnostic for more personalized sleep apnea diagnoses and treatment plans.
The company said that the integration of the two new channels allows EnsoData to improve access and affordability in testing for sleep apnea, which is conventionally screened for through in-office physician visits and sleep-health screening questionnaires, such as the STOP-BANG or Epworth Sleepiness Scale. A mobile app would expand the reach of prescreening for the disorder, which the firm pointed out is both widespread and underdiagnosed.
